Paolo Fundaro - Director, Intercept Pharmaceuticals, Inc

As of May 27, 2022


What is Paolo Fundaro's Net Worth?

The current estimated net worth of Intercept Pharmaceuticals, Inc's Director, Paolo Fundaro, is estimated to be about $205.76M . Paolo Fundaro owns about 4,021,028 units of Intercept Pharmaceuticals, Inc common stock. In the last 10 years at Intercept Pharmaceuticals, Inc, Paolo Fundaro has sold an estimated value of $125.13M worth.

What is Paolo Fundaro's Past Insider Trading?

Paolo Fundaro's largest purchase order was 6,922 units , worth over $59.99K on February 14, 2014. Paolo Fundaro's largest sale order was 1,500,000 units , worth over $71.25M on August 17, 2020. In total, Paolo Fundaro has made about 24 transactions over 10 years of their time at Intercept Pharmaceuticals, Inc. Paolo Fundaro usually trades in May, with the busiest year in 2014.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What is Paolo Fundaro's' Mailing Address?

  • Mailing address is C/o Genextra S.P.A., Via G. de Grassi, 11 Milan L6 20123 Italy

Intercept Pharmaceuticals, Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Mark Pruzanski, M.D., 2020 $757,850 - $4,113,504 $1,015,996 $531,995 $7,660 $6,427,005
Mark Pruzanski, M.D., 2019 $734,292 - $4,197,742 $1,116,118 $560,265 $7,368 $6,615,785
Mark Pruzanski, M.D., 2018 $702,000 - $1,667,718 $1,705,358 $442,260 $8,623 $4,525,960
Jerome Durso, 2020 $599,524 - $2,057,016 $998,776 $231,737 $21,910 $3,908,963
Jerome Durso, 2019 $573,250 - $2,089,570 $1,238,321 $359,284 $21,368 $4,281,793
Jerome Durso, 2018 $540,800 - $1,554,326 $775,844 $292,032 $22,403 $3,185,406
Sandip Kapadia, 2020 $476,863 - $1,087,836 $528,088 $184,039 $21,910 $2,298,736
Sandip Kapadia, 2019 $464,100 - $1,001,664 $586,573 $252,935 $21,368 $2,326,640
Sandip Kapadia, 2018 $442,000 - $790,164 $393,544 $228,735 $22,403 $1,876,846
Richard Kim, 2020 $456,095 - $1,044,360 $505,128 $168,056 $79,211 $2,252,850
Richard Kim, 2019 $442,900 $202,800 $890,368 $521,398 $265,519 $76,343 $2,399,328
Lisa Bright, 2020 $480,552 - $925,704 $453,467 $240,955 $139,106 $2,239,784
Ryan Sullivan, 2020 $437,107 - $1,087,836 $528,088 - $89,942 $2,142,973
Ryan Sullivan, 2019 $445,520 - $1,471,902 $871,713 $267,089 $21,368 $3,077,592
Ryan Sullivan, 2018 $376,158 - $1,239,112 $1,190,351 $229,122 $173,437 $3,208,180
Christian Weyer, M.D., M.A.S., 2020 $486,731 - $925,704 $453,467 $170,804 $21,910 $2,058,616
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1270073/000110465921055639/tm218121-2_def14a.htm

What are Intercept Pharmaceuticals, Inc's Past Insider Trades?

Intercept Pharmaceuticals, Inc's most recent insider trade came on March 12, 2021 by Srinivas Akkaraju who bought 237,000 units worth $5.02M . In the last 9 years, insiders at Intercept Pharmaceuticals, Inc have sold an estimated value of $1.66B and bought an estimated value of $148.73M worth of shares. Insider trading is most common in January, with the busiest year in 2019. The most active traders at the company are David Shapiro, Chief Medical Officer,  Mark Pruzanski, Director,  and Lisa Bright, President .

INTERCEPT PHARMACEUTICALS, INC. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1